For instance, TGF‐β is known to impair anti‐tumor immunity and contribute to tumor escape from immune surveillance, suggesting that inhibiting TGF‐β could enhance the immunotherapeutic effects of CD8+ T cells and NK cells [52]. Here, CD8A is linked to neoplasm.